ReviewDisease markers2014
Biomarkers of inflammatory bowel disease.
Review in Disease markers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: A systematic literature review and meta-analysis.Nutrition & dietetics : the journal of the Dietitians Association of Australia · 2022Pooled it
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.The American journal of gastroenterology · 2015Pooled it
- First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.British journal of clinical pharmacology · 2020Trial
- Hypoallergenic and anti-inflammatory feeds in children with complicated severe acute malnutrition: an open randomised controlled 3-arm intervention trial in Malawi.Scientific reports · 2019Trial
- Connecting the Dots Between Pharmacokinetics, Inflammatory Biomarkers, and Mucosal Healing in Patients on Infliximab with Inflammatory Bowel Disease.Pharmaceutics · 2026Article
- Endoscopic Activity Prediction in Ulcerative Colitis Using Hemogram-Derived Inflammatory Indices: Impact of Azathioprine Use on Diagnostic Performance.Journal of clinical medicine · 2026Article
- Study of serum long non-coding RNA interferon gamma antisense-1 as a biomarker of activity in Crohn's disease.Przeglad gastroenterologiczny · 2026Article
- Advances in biosensors for diagnosis and monitoring of inflammatory bowel disease: A review.Bioengineering & translational medicine · 2025Review
- Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.Biomedicines · 2024Review
- Diagnostic Procedures for Inflammatory Bowel Disease: Laboratory, Endoscopy, Pathology, Imaging, and Beyond.Diagnostics (Basel, Switzerland) · 2024Review
- Recent Trends in Non-Invasive Methods of Diagnosis and Evaluation of Inflammatory Bowel Disease: A Short Review.International journal of molecular sciences · 2024Review
- Hydrogen gas and the gut microbiota are potential biomarkers for the development of experimental colitis in mice.Gut microbiome (Cambridge, England) · 2024Article
- Risk factors affecting relapse after discontinuation of biologics in children with Crohn's disease who maintained deep remission.Frontiers in pediatrics · 2024Article
- Platelet/Albumin ratio and plateletcrit levels are potential new biomarkers for assessing endoscopic inflammatory bowel disease severity.BMC gastroenterology · 2023Article
- Correlation analysis of serum levels of H19 and CRP levels and ulcerative colitis.Journal of medical biochemistry · 2023Article
- Performance of Machine Learning Algorithms for Predicting Disease Activity in Inflammatory Bowel Disease.Inflammation · 2023Article
- Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs?Journal of personalized medicine · 2023Article
- Application of Procalcitonin for the Rapid Diagnosis ofDiagnostics (Basel, Switzerland) · 2022Article
- Elemental, fatty acid, and protein composition of appendicoliths.Scientific reports · 2022Article
- Predictive factors of postoperative fentanyl consumption in patients with inflammatory bowel disease: a retrospective cohort study.BMC anesthesiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic disease mostly involved with intestine with unknown etiology. Diagnosis, evaluation of severity, and prognosis are still present as challenges for physicians. An ideal biomarker with the characters such as simple, easy to perform, noninvasive or microinvasive, cheap, rapid, and reproducible is helpful for patients and clinicians. Currently biomarkers applied in clinic include CRP, ESR, pANCA, ASCA, and fecal calprotectin. However, they are far from ideal. Lots of studies are focused on seeking for ideal biomarker for IBD. Herein, the paper reviewed recent researches on biomarkers of IBD to get advances of biomarkers in inflammatory bowel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.